Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | SNCA | P37840 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254027 | 0.85 | ALDH1A1 (0.66) | KMT2AMEN1GAARAB9ACA9 | |
| SCHEMBL4649471 | 0.83 | KMT2A (0.78) | KMT2AMEN1GAARAB9ASCN2A | |
| SCHEMBL4256256 | 0.81 | CA9 (0.61) | KMT2AMEN1GAARAB9ACA9 | |
| SCHEMBL28839555 | 0.81 | KMT2A (0.67) | KMT2AMEN1GAARAB9ASCN2A | |
| SCHEMBL4251147 | 0.80 | MEN1 (0.53) | KMT2AMEN1GAARAB9ASCN2A | |
| SCHEMBL4257840 | 0.80 | ESR1 (0.73) | KMT2AMEN1GAARAB9ACA9 | |
| SCHEMBL4255818 | 0.80 | MEN1 (0.53) | KMT2AMEN1GAARAB9ACA9 | |
| SCHEMBL4256208 | 0.80 | ALDH1A1 (0.50) | KMT2AMEN1GAARAB9ACA9 | |
| SCHEMBL4249698 | 0.80 | ESR1 (0.67) | KMT2AMEN1GAARAB9ACA9 | |
| SCHEMBL30472945 | 0.79 | ALDH1A1 (0.72) | KMT2AMEN1GAARAB9ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009054653-A2 | ISOINDOLONES WITH HIGH BINDING AFFINITY TO BETA-AMYLOID AGGREGATES AND FIBRILS, AND ITS USE AND PREPARATION METHOD | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-04-30 | — | — | WO | claimed |
| CN-117466799-B | N-substituted phthalic acid diamide preparation method of imine compound | 西北师范大学 | 2024-12-24 | — | — | CN | disclosed |
| CN-117466799-A | Preparation method of N-substituted phthalimide compound | 西北师范大学 | 2024-01-30 | — | — | CN | disclosed |
| US-20210220331-A1 | INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS | THE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2021-07-22 | — | — | US | disclosed |
| US-20210220331-A1 | INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS | THE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2021-07-22 | — | — | US | disclosed |
| EP-3452447-A1 | INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS | The Regents of The University of California (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017192665-A1 | INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017192665-A1 | INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2009054653-A2 | ISOINDOLONES WITH HIGH BINDING AFFINITY TO BETA-AMYLOID AGGREGATES AND FIBRILS, AND ITS USE AND PREPARATION METHOD | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-04-30 | — | — | WO | disclosed |
| US-3966726-A | Process for the production of cyclic carboxylic acid imides | AKZO N.V. (NL) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220331-A1 | INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS | EIF4EBP1, EIF4E, EIF2A | KMT2A 2931/4885MEN1 2048/4885GAA 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.